Method and dyes for detecting and destroying cancer cells

ABSTRACT

This invention relates to new carbocyanine dye compositions, pharmaceutical compositions comprising such compositions, methods of detecting via near infrared fluorescent imaging incipient cancer cells and selective destruction of cancer cells identified by administration of such pharmaceutical compositions. A method of detecting and destroying cancer cells includes introducing a gold dye into an organism suspected of having a cancer cell. The gold dye is a carbocyanine dye covalently attached to a gold nanoparticle. A near infrared light is shined on a region suspected of having the cancer cell. Fluorescence from the gold dye is detected. A beam of radio frequency energy is directed at the region to induce hyperthermia in the cancer cell. The carbocyanine dye has the most basic structure of MHI-148 and structures 6 and 22 with a Au n —[CH 2 (CH 2 ) 9 CH 2 —(OCH 2 CH 2 ) 4 O]COCH 2 CH 2 -phenyl-O group on a cyclohexene ring that imparts activity to the cancer cell binding and destruction processes.

RELATED APLICATIONS

The present invention claims priority on provisional patent application, Ser. No. 61/178,835, filed on May 15, 2009, entitled “Novel Carbocyanine Dyes Bonded to Gold Nano-Particles for the Detection and Therapeutic Treatment of Cancer” and is hereby incorporated by reference.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH

Not Applicable

THE NAMES OF THE PARTIES TO A JOINT RESEARCH AGREEMENT

The present invention was co-developed by CTI and KPS Technologies, LLC.

REFERENCE TO A SEQUENCE LISTING, A TABLE, OR A COMPUTER PROGRAM LISTING

Not Applicable

BACKGROUND OF THE INVENTION

Traditionally cancer has been treated with general radiation treatment and chemotherapy. Both of which have been shown to have a number of side effects. For instance, radiation treatment can result in loss of hair, nausea, and low white cell counts and other side effects such as abdominal pain, nausea, and vomiting. As a result, there has been a constant desire to find cancer treatments with fewer side effects. One solution has been to create RF (Radio Frequency) absorption enhancers that are attached to antibodies that attach to cancer cells. These RF absorption enhancers are very small tuned circuits that induce hyperthermia in the cancer cells to which they are attached when RF energy is directed at them. Unfortunately, these RF absorption enhancers do not provide feedback on where the cancer cells are located. As a result, the RF energy cannot be highly directed to the area with the cancer cells. In addition, these RF absorption enhancers are complex to manufacture.

Thus, there exists a need for an improved method of treating cancer that does not have the side effects of chemotherapy or high intensity radiation treatment and in which the energy used to kill the cancer cells can be highly targeted.

BRIEF SUMMARY OF INVENTION

This invention relates to new carbocyanine dye compositions, pharmaceutical compositions comprising such compositions, methods of detecting via near infrared fluorescent imaging incipient cancer cells and selective destruction of cancer cells identified by administration of such pharmaceutical compositions.

A method of detecting and destroying cancer cells includes introducing a gold dye into an organism suspected of having a cancer cell. The gold dye is a carbocyanine dye covalently attached to a gold nanoparticle. A near infrared excitation light source is scanned on a region suspected of having the cancer cells. Fluorescence emitted from the excited gold dye is detected by near infrared imaging techniques. A beam of radio frequency energy is directed at the near infrared fluorescence imaged region to induce hyperthermia in the cancer cell. In one embodiment, the carbocyanine dye has the most basic structure of MHI-148 with a Au_(n)—[S—CH₂(CH₂)₉CH₂—(OCH₂CH₂)₄O]COCH₂CH₂-phenyl-O group on a cyclohexene ring that imparts activity to the cancer cell binding and destruction processes. Note that multiple gold atoms may be attached to the phenyl-O group. In another embodiment, silver, copper or another metal may be substituted for gold.

These gold dyes are easy to produce and comparatively inexpensive. The gold dye is rapidly eliminated from the healthy cells and tissue either via urinary and fecal routes with no accumulation in the healthy tissue. Certain gold dye structures with optimized total charge on the molecule have been discovered that avoid passage through the liver during clean out from the body. Any side effects of the process are therefore minimized.

BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS

FIG. 1 is a flow chart of the steps used in a method for detecting and destroying cancer cells.

DETAILED DESCRIPTION OF THE INVENTION

The invention relates to new carbocyanine dye compositions, pharmaceutical compositions comprising such compositions, methods of detecting via near infrared fluorescent imaging incipient cancer cells and selective destruction of cancer cells identified by administration of such pharmaceutical compositions.

FIG. 1 is a flow chart of the steps used in a method for detecting and destroying cancer cells. The process starts, step 10, by introducing a gold dye into an organism suspected of having cancer at step 12. The gold dye is a carbocyanine dye covalently attached to a metal nanoparticle. In a preferred embodiment, the metal nanoparticle is gold. Near infrared light is shone on a region of the organism suspected of having cancer cells at step 14. Fluorescence from the gold dye is detected at step 16. The gold dye adheres to cancer cells and any excess of the gold dye is quickly flushed from organism's body. As a result, fluorescence only occurs in areas that have cancer cells. At step 18, a beam of radio frequency energy is directed at the region to induce hyperthermia in the cancer cell, which ends the process at step 20.

The gold dye is flushed from the body along with the dead cancer cells. A number of mechanisms have been hypothesized as to why the gold dye induces hyperthermia and this invention is not limited to any specific theory. It is known that metal particles less than 100 micrometers are heated by microwave energy. One theory is that the metal nanoparticles are directly heated by the microwave energy. It is possible that the magnetic field of the radio frequency energy induces inductive heating of the metal nanoparticles. The optimum frequency of the radio waves can be determined by measuring the heat output versus the frequency. The heat output can be measured using an infrared thermal camera.

The carbocyanine dye of the gold dye is known to absorb light in the near infrared spectrum from 680 to 1200 nm and to fluoresce in the near infrared spectrum at longer wavelengths. These carbocyanine dyes have been shown to selectively bind to cancer cells and cancerous tissue.

Specific structures were designed that selectively bind to cancer cells and cancerous tissue in-vitro and in-vivo after covalent attachment of one or more carbocyanine dye molecule to gold nanoparticles. Gold particles that do not have dyes attached to their surface are separated and not used. A specific dye composition that facilitates the transport of gold particles synthesized according to Scheme 1 selectively binds to cancer cells in-vivo and accumulate in tumors. Any non-binding gold dye cleans out rapidly without toxic effects. The example dye shown here contains bromide counter anions but in manufactured pharmaceutical compositions the bromide will be changed to a pharmaceutically acceptable carrier or excipient such as citrate, tartrate, etc. Such carriers or excipients refer to an excipient that can be included in the compositions of the invention and that causes no significant adverse toxicological effects to the patient.

Note that the final structure of scheme 2 is structure 6 and the final structure of scheme 3 is structure 22.

The preferred formula 1-8 of the carbocyanine dyes for the present invention have a Au_(n)—[S—CH₂(CH₂)₉CH₂—(OCH₂CH₂)₄O]COCH₂CH₂-phenyl-O group on the cyclohexene or cyclopentene ring of the heptacyanine structures disclosed that may have a significant role in the described retaining and toxicity properties. In the preferred embodiment, heptamethine cyanine dyes are synthesized. The preferred heptamethine cyanines absorb light efficiently and have maximum absorption wavelengths in the region of 780 to 1100 nm. This wavelength is suitable for reducing background fluorescence in vivo and corresponds to the radiation wavelength of the GaAlAs diode laser and other semiconductor light sources.

Some of these compounds in formula 1-8 and the compounds shown in Scheme 1 have variable water solubility, near infrared fluorescent spectral properties suitable for in-vivo tissue imaging (e.g. MHI-148 has λ_(max) absorption 780 nm and high intensity λ_(max) emission 800 nm (FIG. 1)), and have been tested to have similar activities in near infrared fluorescent imaging of tumor cells and inhibiting tumor cell growth in vitro, and permit selective destruction of any gold labeled cancer cells via radiofrequency treatment. The solubility of the labeled gold particles may be controlled by the dye molecules attached to the surface of gold particles or by additional solubilization groups attached to the gold particle surface as it is described by the literature or by prior art. Biodistribution of these gold particles are determined by the molecules attached to the gold particle surface and particle size.

-   -   R2=H, EWG, EDG in 4, 4′, 5, 5′, 6, 6′, 7, 7′, 8, 8′, 9, 9′         positions     -   R1=H, Alkyl, Aryl, Aralkyl, RSO0 ₃ ⁻, RCOO⁻, RNH₂     -   A=I, Cl, Br, OSO₂Aryl, OSO₂R, BF₄, ClO₄, or pharmaceutically         acceptable carrier anion such as citrate, tartrate     -   X═Au_(n)—[S—CH₂(CH₂)₉CH₂—(OCH₂CH₂)₄O]COCH₂CH₂-phenyl-O, or     -   Au_(n)—[S—(CH₂)₉—S n=a subscript meaning n=1-20 atoms

-   -   R2=H, EWG, EDG in 4, 4′, 5, 5′, 6, 6′, 7, 7′, 8, 8′, 9, 9′         positions     -   R1=H, Alkyl, Aryl, Aralkyl, RSO₃ ⁻, RCOO⁻, RNH₂     -   A=I, Cl, Br, OSO₂Aryl, OSO₂R, BF₄, ClO₄, or pharmaceutically         acceptable carrier anion such as citrate, tartrate     -   X═Au_(n)—[S—CH₂(CH₂)₉CH₂—(OCH₂CH₂)₄O]COCH₂CH₂-phenyl-O, or     -   Au_(n)—[S—(CH₂)_(g)—S n=a subscript meaning n=1-20 atoms

-   -   R2=H, EWG, EDG in 4, 4′, 5, 5′, 6, 6′, 7, 7′, 8, 8′, 9, 9′         positions     -   R1=H, Alkyl, Aryl, Aralkyl, RSO₃ ⁻, RCOO⁻, RNH₂     -   A=I, Cl, Br, OSO₂Aryl, OSO₂R, BF₄, ClO₄, or pharmaceutically         acceptable carrier anion such as citrate, tartrate     -   X=Au_(n)—[S—CH₂(CH₂)₉CH₂—(OCH₂CH₂)₄O]COCH₂CH₂-phenyl-O, or     -   Au_(n)—[S—(CH₂)₉—S n=a subscript meaning n=1-20 atoms

-   -   R2=H, EWG, EDG in 4, 4′, 5, 5′, 6, 6′, 7, 7′, 8, 8′, 9, 9′         positions     -   R1=H, Alkyl, Aryl, Aralkyl, RSO₃ ⁻, RCOO⁻, RNH₂     -   A=I, Cl, Br, OSO₂Aryl, OSO₂R, BF₄, ClO₄, or pharmaceutically         acceptable carrier anion such as citrate, tartrate     -   X═Au_(n)—[S—CH₂(CH₂)₉CH₂—(OCH₂CH₂)₄O]COCH₂CH₂-phenyl-O, or     -   Au_(n)—[S—(CH₂)₉—S n=a subscript meaning n=1-20 atoms

-   -   R2=H, EWG, EDG in 4, 4′, 5, 5′, 6, 6′, 7, 7′, 8, 8′, 9, 9°         positions     -   R1=H, Alkyl, Aryl, Aralkyl, RSO₃ ⁻, RCOO⁻, RNH₂     -   A=I, Cl, Br, OSO₂Aryl, OSO₂R, BF₄, ClO₄, or pharmaceutically         acceptable carrier anion such as citrate, tartrate     -   X═Au_(n)—[S—CH₂(CH₂)₉CH₂—(OCH₂CH₂)₄O]COCH₂CH₂-phenyl-O, or     -   Au_(n)—[S—(CH₂)₉—S n=a subscript meaning n=1-20 atoms

-   -   R2=H, EWG, EDG in 4, 4′, 5, 5′, 6, 6′, 7, 7′, 8, 8′, 9, 9′         positions     -   R1=H, Alkyl, Aryl, Aralkyl, RSO₃ ⁻, RCOO⁻, RNH₂     -   A=I, Cl, Br, OSO₂Aryl, OSO₂R, BF₄, ClO₄, or pharmaceutically         acceptable carrier anion such as citrate, tartrate     -   X═Au_(n)—[S—CH₂(CH₂)₉CH₂—(OCH₂CH₂)₄O]COCH₂CH₂-phenyl-O, or

Au_(n)—[S—(CH₂)₉—S n=a subscript meaning n=1-20 atoms

-   -   R2=H, EWG, EDG in 3, 3′, 4, 4′, 5, 5′, 6, 6′, 7, 7′, 8, 8′         positions     -   R1=H, Alkyl, Aryl, Aralkyl, RSO₃ ⁻, RCOO⁻, RNH₂     -   A=I, Cl, Br, OSO₂Aryl, OSO₂R, BF₄, ClO₄, or pharmaceutically         acceptable carrier anion such as citrate, tartrate     -   X═Au_(n)—[S—CH₂(CH₂)₉CH₂—(OCH₂CH₂)₄O]COCH₂CH₂-phenyl-O, or     -   Au_(n)—[S—(CH₂)₉—S n=a subscript meaning n=1-20 atoms

-   -   R2=H, EWG, EDG in 3, 3′, 4, 4′, 5, 5′, 6, 6′, 7, 7′, 8, 8′         positions     -   R1=H, Alkyl, Aryl, Aralkyl, RSO₃ ⁻, RCOO⁻, RNH₂     -   A=I, Cl, Br, OSO₂Aryl, OSO₂R, BF₄, ClO₄, or pharmaceutically         acceptable carrier anion such as citrate, tartrate     -   X═Au_(n)—[S—CH₂(CH₂)₉CH₂—(OCH₂CH₂)₄O]COCH₂CH₂-phenyl-O, or     -   Au_(n)—[S—(CH₂)₉—S n=a subscript meaning n=1-20 atoms

-   Formula 1 shows cyanine dyes having the most basic structure of     MHI-148 with a Au_(n)—[S—CH₂(CH₂)₉CH₂—(OCH₂CH₂)₄O]COCH₂CH₂-phenyl-O     group on a cyclohexene ring that imparts activity to the cancer cell     binding and destruction processes. In this embodiment, when X is     Au_(n)—[S—CH₂(CH₂)₉CH₂—(OCH₂CH₂)₄O]COCH₂CH₂-phenyl-O group, the     maximum absorbance wavelength is between 770 and 780 nm, depending     on the solvent and the maximum emission wavelength (maximum quantum     yield and lambda fluorescent light) is between 805 and 820 depending     on the solvent. -   Formula 2 shows cyanine dyes having an extended conjugation in the     heterocyclic moiety and containing cyclopentene ring. In this     embodiment, when X is a     Au_(n)—[S—CH₂(CH₂)₉CH₂—(OCH₂CH₂)₄O]COCH₂CH₂-phenyl-O group, the     maximum absorbance wavelength is between 790 and 800 nm, depending     on the solvent and the maximum emission wavelength (maximum quantum     yield and lambda fluorescent light) is between 810 and 820 nm     depending on the solvent. This extended conjugation slightly     increases the absorption and emission wavelengths and at the same     time increases the hydrophobicity of the molecule that seems to be     an important factor in dye retention by the cancer cells. -   Formula 3 shows cyanine dyes having a five member ring in the center     of the molecule. In this embodiment, when X is with a     Au_(n)—[S—CH₂(CH₂)₉CH₂—(OCH₂CH₂)₄O]COCH₂CH₂-phenyl-O group, the     maximum absorbance wavelength is between 770 and 790 nm, depending     on the solvent and the maximum emission wavelength (maximum quantum     yield and lambda fluorescent light) is between 790 and 810 nm,     depending on the solvent. The five member ring may slightly increase     the reactivity of the halogen for reactions leading to Au dyes.     Note, the kill mechanism in this invention is RF energy and     localized heating of cancer cells near to the Au dye. -   Formula 4 shows cyanine dyes having an extended conjugation in the     heterocyclic moiety and containing the five member central ring. In     this embodiment, when X is     Au_(n)—[S—CH₂(CH₂)₉CH₂—(OCH₂CH₂)₄O]COCH₂CH₂-phenyl-O group, the     maximum absorbance wavelength is between 770 and 790 nm, depending     on the solvent and the maximum emission wavelength (maximum quantum     yield and lambda fluorescent light) is between 790 and 810 nm     depending on the solvent. This extended conjugation slightly     increases the absorption and emission wavelengths and at the same     time increases the hydrophobicity of the molecule that seems to be     an important factor in dye retention by the cancer cells. -   Formula 5 shows cyanine dyes having an extended conjugation in the     heterocyclic moiety and containing the six member central ring. In     this embodiment, when X is     Au_(n)—[S—CH₂(CH₂)₉CH₂—(OCH₂CH₂)₄O]COCH₂CH₂-phenyl-O group, the     maximum absorbance wavelength is between 770 and 790 nm, depending     on the solvent and the maximum emission wavelength (maximum quantum     yield and lambda fluorescent light) is between 790 and 810 nm     depending on the solvent. This extended conjugation slightly     increases the absorption and emission wavelengths and at the same     time increases the hydrophobicity of the molecule that seems to be     an important factor in dye retention by the cancer cells. -   Formula 6 shows cyanine dyes having an extended conjugation in the     heterocyclic moiety and containing the five member central ring. In     this embodiment, when X is     Au_(n)—[S—CH₂(CH₂)₉CH₂—(OCH₂CH₂)₄O]COCH₂CH₂-phenyl-O group, the     maximum absorbance wavelength is between 770 and 810 nm, depending     on the solvent and the maximum emission wavelength (maximum quantum     yield and lambda fluorescent light) is between 790 and 810 nm     depending on the solvent. This extended conjugation slightly     increases the absorption and emission wavelengths and at the same     time increases the hydrophobicity of the molecule that seems to be     an important factor in dye retention by the cancer cells. -   Formula 7 shows synthesized cyanine dyes having an extended     conjugation in the heterocyclic moiety and containing the six member     central ring. In this embodiment, when X is     Au_(n)—[S—CH₂(CH₂)₉CH₂—(OCH₂CH₂)₄O]COCH₂CH₂-phenyl-O group, the     maximum absorbance wavelength is between 980 and 1000 nm, depending     on the solvent and the maximum emission wavelength (maximum quantum     yield and lambda fluorescent light) is between 1000 and 1020 nm     depending on the solvent. This extended conjugation substantially     increases the absorption and emission wavelengths and at the same     time increases the hydrophobicity of the molecule that seems to be     an important factor in dye retention by the cancer cells. -   Formula 8 shows synthesized cyanine dyes having an extended     conjugation in the heterocyclic moiety and containing the five     member central ring. In this embodiment, when X is     Au_(n)-[S—CH₂(CH₂)₉CH₂—(OCH₂CH₂)₄O]COCH₂CH₂-phenyl-O group, the     maximum absorbance wavelength is between 980 and 1000 nm, depending     on the solvent and the maximum emission wavelength (maximum quantum     yield and lambda fluorescent light) is between 1000 and 1020 nm     depending on the solvent. This extended conjugation substantially     increases the absorption and emission wavelengths and at the same     time increases the hydrophobicity of the molecule that seems to be     an important factor in dye retention by the cancer cells.

Other suitable dyes include but not limited to unsymmetrical tricarbocyanine, pentacyanine and heptacyanine structures functionalized with gold nanoparticles 3.5-5 nm (TEM) as indicated in Formula 9 which absorb light having the wavelengths in the region of 680 to 760 nm.

Formulas 1-9 show a variety of carbocyanines dyes attached to a metal nanoparticle (gold dye) that selectively attach to cancer cell. The carbocyanine dye fluoresces in the near infrared range and can be activated by light in the near infrared spectrum. These gold dyes are quickly flushed from the body except for those molecules that attach to cancer cells. When the gold dye is attached to a cancer cell or cancerous tissue and a RF field is applied the cancers material undergoes hyperthermia and is destroyed. Very little of the surrounding healthy tissue is affected.

Thus there has been described an improved method of treating cancer that does not have the side effects of chemotherapy or radiation treatment and in which the energy used to kill the cancer cells can be highly targeted.

While the invention has been described in conjunction with specific embodiments thereof, it is evident that many alterations, modifications, and variations will be apparent to those skilled in the art in light of the foregoing description. Accordingly, it is intended to embrace all such alterations, modifications, and variations in the appended claims. 

What is claimed is:
 1. A method of detecting and destroying cancer cells, comprising the steps of: introducing a gold dye into an organism suspected of having a cancer cell, wherein the gold dye is a carbocyanine dye covalently attached to a metal nanoparticle; shinning a near infrared light on a region suspected of having the cancer cell; detecting a fluorescence from the gold dye; targeting a beam of radio frequency energy at the region to induce hyperthermia in the cancer cell.
 2. The method of claim 1, further including the step of not inducing hyperthermia in non-cancer cells near the cancer cell.
 3. The method of claim 1, wherein the step of introducing the gold dye includes attaching the metal nanoparticle by an Au_(n)—[S—CH2(CH2)9CH2-(OCH2CH2)4O]COCH2CH2-phenyl-O group on a cyclohexene ring of the carbocyanine dye.
 4. The method of claim 3, further including synthesizing the carbocyanine dye represented by Formula
 1. 5. The method of claim 4, wherein the gold nanoparticle is attached to a cyclohexene ring of the carbocyanine dye.
 6. The method of claim 1, wherein the step of shinning the near infrared light includes the step of selecting a GaAlAs diode laser with a predetermined wavelength.
 7. A heptamethine cyanine dye covalently attached to a metal particle having a maximum absorption wavelength in the region between 780 and 1100nm.
 8. The heptamethine cyanine dye of claim 7, wherein the heptamethine cyanine dye is represented by Formula
 1. 9. The heptamethine cyanine dye of claim 7, wherein the heptamethine cyanine dye is represented by Formula
 2. 10. The heptamethine cyanine dye of claim 7, wherein the heptamethine cyanine dye is represented by Formula
 3. 11. The heptamethine cyanine dye of claim 7, wherein the heptamethine cyanine dye is represented by Formula
 4. 12. The heptamethine cyanine dye of claim 7, wherein the heptamethine cyanine dye is represented by Formula
 5. 13. The heptamethine cyanine dye of claim 7, wherein the heptamethine cyanine dye is represented by Formula
 6. 14. The heptamethine cyanine dye of claim 7, wherein the heptamethine cyanine dye is represented by Formula
 7. 15. The heptamethine cyanine dye of claim 7, wherein the heptamethine cyanine dye is represented by Formula
 8. 16. The heptamethine cyanine dye of claim 7, wherein the bromide counter anions are replaced with an pharmaceutically acceptable carrier.
 17. The heptamethine cyanine dye of claim 7, wherein the bromide counter anions are replaced with an pharmaceutically acceptable excipient.
 18. An unsymmetrical cyanine dye with a covalently attached to a metal particle as represented in Formula 9 having a maximum absorption wavelength in the region between 680 to 760 nm.
 19. The unsymmetrical cyanine dye of claim18, wherein the unsymmetrical cyanine dye is a tricarbocyanine.
 20. The unsymmetrical cyanine dye of claim18, wherein the unsymmetrical cyanine dye is a pentacarbocyanine.
 21. The unsymmetrical cyanine dye of claim 18, wherein the unsymmetrical cyanine dye is a heptacarbocyanine.
 22. A symmetrical cyanine dye of the structure
 6. 23. A symmetrical cyanine dye of the structure
 22. 24. A symmetrical cyanine dye of structure 6 attached to a functionalized gold nanoparticle AuS—[CH2]9-(OCH2CH2)4OH via an ester bond.
 25. A symmetrical cyanine dye of structure 6 attached to a functionalized gold nanoparticle Au—S—[CH2]9NH2 via an amide bond.
 26. A symmetrical cyanine dye of structure 6 attached to a functionalized gold nanoparticle Au—S—[CH2]9-SH via a thioester bond
 27. A symmetrical cyanine dye of structure 22 attached to a functionalized gold nanoparticle AuS—[CH2]9-(OCH2CH2)4OH via an ester bond.
 27. A symmetrical cyanine dye of structure 22 attached to a functionalized gold nanoparticle Au—S—[CH2]9NH2 via an amide bond.
 28. A symmetrical cyanine dye of formula 22 attached to a functionalized gold nanoparticle Au—S—[CH2]9-SH via a thioester bond.
 29. A symmetrical cyanine dye of structure 6 or 22 in which the O-phenyl-CH2CH2CO2H group is replaced by S[CH2]9S-Au_(n). 